Folia Health today announced a collaboration with argenx to launch a first-of-its-kind, at-home observational real-world evidence initiative supporting individuals living with chronic inflammatory ...
Amsterdam, The Netherlands – July 17, 2023 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...
This week, we are going to continue down the road of autoimmune peripheral nerve conditions to discuss two that we have touched on in the past—Guillain-Barré Syndrome and CIDP (chronic inflammatory ...
Standard treatment for many autoimmune diseases includes drugs that suppress the immune system. Even when this approach works (and it doesn’t work for everyone), chronic immunosuppression puts ...
(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results